Quick Answer
Esperion Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $167.85 million for the year ending 2025.
- Esperion Therapeutics, Inc. showed an increase of +16.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Esperion Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), Esperion Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 4,815.3%.
- Historical annual values: Fiscal year 2025: $167.85 million | Fiscal year 2024: $144.76 million | Fiscal year 2023: $82.25 million | Fiscal year 2022: $124.78 million | Fiscal year 2021: $208.89 million | Fiscal year 2020: $304.96 million | Fiscal year 2019: $166.13 million | Fiscal year 2018: $36.97 million | Fiscal year 2017: $34.47 million | Fiscal year 2016: $38.17 million | Fiscal year 2015: $77.34 million | Fiscal year 2014: $85.04 million | Fiscal year 2013: $56.54 million | Fiscal year 2012: $6.51 million | Fiscal year 2011: $1.57 million | Fiscal year 2010: $3.41 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: